Associated Papers
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
Turner NC et al.
Npj Breast Cancer, 2023
37803017 (PubMed )
Supplement: 41523_2023_561_MOESM1_ESM.pdf
Human BRCA pathogenic variants were originated during recent human history.
Li J et al.
Life Science Alliance, 2022
35165121 (PubMed )
Supplement: LSA-2021-01263_TableS2.xlsx › BRCA1
Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
Bhaskaran SP et al.
International Journal of Cancer, 2019
30702160 (PubMed )
Supplement: IJC-145-962-s005.xlsx › dbBRCA2
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.
Ławniczak M et al.
Hereditary Cancer in Clinical Practice, 2016
Recurrent mutations of BRCA1 and BRCA2 in Poland: an update.
Szwiec M et al.
Clinical Genetics, 2015
High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer.
Gaj P et al.
Familial Cancer, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
Finkelman BS et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2012
Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland.
Balabas A et al.
Familial Cancer, 2010
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R et al.
Jama, 2005
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Pohlreich P et al.
Breast Cancer Research : Bcr, 2005
Select a paper to view details